Related Experiment Videos
Enzyme immunoassay for 4-hydroxy-2-(4-methylphenyl)benzothiazole
Journal of Pharmaceutical and Biomedical Analysis
|June 1, 1993
Summary
A new enzyme immunoassay (EIA) accurately measures KB-2714, an active metabolite of the anti-rheumatic drug KB-2683. This sensitive and specific assay is suitable for determining KB-2714 levels in biological samples like urine and plasma.
Area of Science:
- Analytical Chemistry
- Biochemistry
- Pharmacology
Background:
- KB-2683 is a promising anti-rheumatic agent.
- KB-2714 is the active metabolite of KB-2683.
- Accurate quantification of metabolites is crucial for drug development and therapeutic monitoring.
Purpose of the Study:
- To develop and validate a sensitive and specific enzyme immunoassay (EIA) for quantifying 4-hydroxy-2-(4-methylphenyl)benzothiazole (KB-2714).
- To assess the utility of the developed EIA for determining KB-2714 in biological matrices.
Main Methods:
- Development of a bridge heterologous enzyme immunoassay (EIA) using specific antiserum and a beta-galactosidase-labelled antigen.
- Characterization of EIA performance, including sensitivity, specificity, and dose-response range.
- Validation of the EIA method for quantifying KB-2714 in human urine and plasma samples.
Main Results:
- The EIA demonstrated high sensitivity, with a dose-response curve obtained in the range of 10 pg/tube to 20 ng/tube.
- The assay exhibited satisfactory specificity, with minimal cross-reactivity to related benzothiazole compounds and their conjugates.
- The method provided acceptable recovery and precision for both inter- and intra-assay variability in urine and plasma.
Conclusions:
- A sensitive and specific EIA has been successfully developed for the quantification of KB-2714.
- The developed EIA method is suitable for the determination of KB-2714 in biological samples, supporting pharmacokinetic and pharmacodynamic studies of KB-2683.